PUBLICATION

Global Business Reports

AUTHORS

JP Stevenson, Clotilde Bonetto Gandolfi

Turkey Pharmaceuticals Manufacturing 2014

June 02, 2014

Estimated to reach a value of $36 billion by 2023, Turkey’s pharmaceuticals manufacturing industry shows strong growth potential. Government support, high technological standards, and logistical advantages make Turkey an excellent place to manufacture and export pharmaceuticals. If the public and private sectors can collaborate to improve practices and profit margins, the country will become a global pharmaceuticals powerhouse.

RELATED INTERVIEWS MORE INTERVIEWS

Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Piramal Pharma updates GBR in its recent developments and prospects.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.

RECENT PUBLICATIONS

Africa Energy 2025

GBR is pleased to release its Africa Energy 2025 report, following four months of interviews and research across Sub-Saharan Africa, during which time we met with over 120 companies, including those in the upstream, midstream, and downstream sectors, as well as governments, financiers, and service providers.

MORE PREVIOUSLY PUBLISHED

MACIG

"In a high-risk, high-capital sector like mining, getting that perspective from an experienced partner with decades of hands-on experience can be game-changing."

SUBSCRIBE TO OUR NEWSLETTER